Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma

Multiple myeloma (MM) has a worldwide incidence of 1–5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferat...

Descripción completa

Detalles Bibliográficos
Autores principales: Swan, Dawn, Lynch, Kevin, Gurney, Mark, O’Dwyer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582283/
https://www.ncbi.nlm.nih.gov/pubmed/31244984
http://dx.doi.org/10.1177/2040620719854171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582283/
https://www.ncbi.nlm.nih.gov/pubmed/31244984
http://dx.doi.org/10.1177/2040620719854171

Ejemplares similares